Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Head & Neck 1Breast 1

Conditions

Head and Neck Neoplasms 174Squamous Cell Carcinoma of Head and Neck 147Nasopharyngeal Carcinoma 126Oropharyngeal Neoplasms 25Thyroid Neoplasms 23Nasopharyngeal Neoplasms 21Mouth Neoplasms 21Carcinoma, Squamous Cell 19Laryngeal Neoplasms 17Neoplasms 15Radiation Injuries 13Hypopharyngeal Neoplasms 13Salivary Gland Neoplasms 11Carcinoma 11Stomatitis 10Recurrence 10Laryngeal Diseases 10Tongue Neoplasms 9Mucositis 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pain 7Neoplasm Metastasis 7Esthesioneuroblastoma, Olfactory 7Xerostomia 6Uterine Cervical Neoplasms 6Differentiated Thyroid Cancer 6Breast Neoplasms 6Thyroid Cancer, Papillary 5Parathyroid Neoplasms 4Melanoma 4

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma in Situ × Head & Neck × Clear all
NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

M.D. Anderson Cancer Center

Phase 3 Completed
303 enrolled 11 charts
Head & Neck

Carcinoma in Situ, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡